---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-328747"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2025-12-22T23:59:59+00:00"
generated_at: "2026-05-16T12:25:34.502075+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fulgent Genetics to acquire Bako Diagnostics and StrataDx for $55.5M total

## Summary
- Acquires equity of StrataDx for $12.5M cash; asset purchase from Bako entities for $43.0M cash.
- Deal expected to close in first half 2026; subject to regulatory approvals and customary conditions.
- Adds anatomic pathology, proprietary PCR tests, nationwide sales team, and CLIA/CAP labs in GA and MA.
- Fulgent plans to leverage AI and digital pathology (Eziopath) to improve efficiency at acquired labs.
- Acquisition funded from cash on hand; Fulgent notes organic double-digit growth in lab services business.

## SEC filing metadata
- accession: 0001193125-25-328747
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2025-12-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000119312525328747/0001193125-25-328747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000119312525328747/flgt-20251220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-328747
- JSON: https://secwatch.observer/filing/0001193125-25-328747.json
- Plain text: https://secwatch.observer/filing/0001193125-25-328747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.